Blind E - Search Results

1

The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.

Blind E, de Graeff PA, Meurs I, Holtkamp F, Baczynska A, Janssen H. Blind E, et al. Eur Heart J. 2015 Dec 27:ehv673. doi: 10.1093/eurheartj/ehv673. Online ahead of print. Eur Heart J. 2015. PMID: 26712836 No abstract available.

2

CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.

Blind E, de Graeff PA, Meurs I, Holtkamp F, Baczynska A, Janssen H. Blind E, et al. Eur Heart J. 2016 Feb 7;37(6):502-3. doi: 10.1093/eurheartj/ehv685. Eur Heart J. 2016. PMID: 26853264 No abstract available.

3

Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.

Dunder K, de Graeff PA, Blind E. Dunder K, et al. Among authors: blind e. Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):129. doi: 10.1093/ehjcvp/pvx006. Eur Heart J Cardiovasc Pharmacother. 2017. PMID: 28444250 No abstract available.

4

The European Medicines Agency's approval of new medicines for type 2 diabetes.

Blind E, Janssen H, Dunder K, de Graeff PA. Blind E, et al. Diabetes Obes Metab. 2018 Sep;20(9):2059-2063. doi: 10.1111/dom.13349. Epub 2018 May 30. Diabetes Obes Metab. 2018. PMID: 29740935 Free PMC article. Review.

5

Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C. Egan AG, et al. Among authors: blind e. N Engl J Med. 2014 Feb 27;370(9):794-7. doi: 10.1056/NEJMp1314078. N Engl J Med. 2014. PMID: 24571751 Free article. No abstract available.

6

Rosiglitazone: a European regulatory perspective.

Blind E, Dunder K, de Graeff PA, Abadie E. Blind E, et al. Diabetologia. 2011 Feb;54(2):213-8. doi: 10.1007/s00125-010-1992-5. Epub 2010 Dec 14. Diabetologia. 2011. PMID: 21153629 No abstract available.

7

Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective.

Kehoe T, Blind E, Janssen H. Kehoe T, et al. Among authors: blind e. Br J Clin Pharmacol. 2019 Jun;85(6):1208-1212. doi: 10.1111/bcp.13791. Epub 2018 Dec 3. Br J Clin Pharmacol. 2019. PMID: 30335197 Free PMC article. Review.

8

Twenty years of progress with parathyroid hormone (PTH): from specialized and "difficult" measurement to common laboratory parameter and treatment option in osteoporosis.

Blind E. Blind E. Clin Lab. 2008;54(11-12):439-49. Clin Lab. 2008. PMID: 19216250 Review. No abstract available.

9

Circulating levels of midregional parathyroid hormone-related protein in hypercalcaemia of malignancy.

Blind E, Raue F, Götzmann J, Schmidt-Gayk H, Kohl B, Ziegler R. Blind E, et al. Clin Endocrinol (Oxf). 1992 Sep;37(3):290-7. doi: 10.1111/j.1365-2265.1992.tb02324.x. Clin Endocrinol (Oxf). 1992. PMID: 1424212

10

Intact parathyroid hormone in primary hyperparathyroidism.

Flentje D, Schmidt-Gayk H, Fischer S, Stern J, Blind E, Buhr H, Herfarth C. Flentje D, et al. Among authors: blind e. Br J Surg. 1990 Feb;77(2):168-72. doi: 10.1002/bjs.1800770217. Br J Surg. 1990. PMID: 2317677

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters